Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 21:00:00 11/02/2026 GMT			5-day change	1st Jan Change
15.25 ^USD	0.00%		+5.76%	-12.81%

02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	Avacta Therapeutics Announces Executive Changes	CI

Transcript : Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09

Published on 01/12/2026 at 06:50 pm GMT - Modified on 01/12/2026 at 08:50 pm GMT

S&P Capital IQ

Presenter Speech
Mahkam Zanganeh (Executives)

Good afternoon. Thank you for joining us today, and thank you for JPMorgan for having us today to present at this conference. I'm Dr. Maky Zanganeh,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Summit Therapeutics Inc.

02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	Avacta Therapeutics Announces Executive Changes	CI
01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
01-29	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab	MT
01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
01-12	Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:45 AM
01-12	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy	MT
01-12	Summit Therapeutics Files Marketing Application for Lung Cancer Therapy	MT
01-12	Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate	CI
12-17	Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16	MT
12-09	Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	CI
12-03	Summit Therapeutics Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02:10 PM
12-02	Summit Therapeutics Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10:30 AM
11-18	Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03:30 PM
11-10	Summit Therapeutics Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 03:30 PM
11-07	Akeso Announces Final OS Analysis Results Of Ivonescimab HARMONi-A Study At SITC 2025	CI
11-07	Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer	MT
24/10/25	Summit Therapeutics Insider Bought Shares Worth $9,999,983, According to a Recent SEC Filing	MT
22/10/25	Summit Therapeutics Raises $500 Million Via Private Placement	MT
22/10/25	Summit Therapeutics raises $500 million in private placement	RE
21/10/25	The Calm Before the Quarterly Storm
21/10/25	Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley…
20/10/25	Summit Therapeutics Inc. announced that it expects to receive $500.036534 million in funding	CI